The Express Tribune1d
Deregulation boosts pharma profits by 210% YoY
Owing to deregulated prices, Pakistan's pharmaceutical sector witnessed a remarkable surge in profitability, posting a 210% ...
GSK's Vaccine and HIV Portfolios Support Ongoing Innovation in Oncology and Immunology
GSK remains on fairly stable financial footing, with a debt/EBITDA ratio of 2.8 at the end of 2024 and Haleon taking on close to GBP 10 billion of GSK's debt in the 2022 divestment. With the improving ...
‘I’m not trying to turn GSK into Google’: How GSK’s Silicon Valley veteran has transformed the pharma giant into a tech powerhouse
For GSK’s Ramakrishnan, who has served as CDTO since 2021, the biggest challenge was helping her company get a head start in ...
The fall of 23andMe: How DNA testing lost its way
23andMe is a company on the ropes having filed for bankruptcy in the US. The one-time leader of the DNA analysis market – valued at $6 billion in 2021 – is now worth less than $50 million, a 99 ...